Company intelligence / Profile preview

Cardio Flow

St Paul, Minnesota, United Stateszoominfo.com ↗

Ownership: Private
Development stage: Other

Overview

FreedomFlow Orbital Atherectomy Platform received FDA clearance in September 2023 and has completed its first commercial cases in the U.S., demonstrating effectiveness in treating complex PAD lesions, including chronic total occlusions with extensive calcification. The platform offers versatility for treating multiple blockages across a wide range of vessel diameters with a single device.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Cardio Flow.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardio Flow.

Explore the full profile